StockNews.AISignal intelligence
Company intelligence

PFE

Pfizer Inc. · NYQ · Healthcare

Price$27.40-0.51% · −$0.14
Market cap156.18BEquity value
P / E9.0Trailing ratio
Volume38.29MLatest session
Market data

PFE price chart

TradingView
Related signals
1 min delayed

Browse public PFE signals with their source context and measured market impact. Open any signal for its permanent analysis page.

PFENov 3, 2026+0.24% since signal

Pfizer raises annual forecast on Eliquis and oncology drug momentum

Pfizer topped expectations in the third quarter and boosted its full-year outlook thanks to solid demand for Eliquis and cancer therapies. The results point to improving cash flow and stronger growth across key franchises, with Eliquis carrying much of the upside. Investors will scrutinize the magnitude of guidance lift and any upcoming pipeline catalysts.

View signal analysis
PFEOct 27, 2026-0.96% since signal

Pfizer's Elrexfio Phase 3 shows strong PFS signals in multiple myeloma

Pfizer reported topline Phase 3 MagnetisMM-32 results for Elrexfio as monotherapy in relapsed/refractory multiple myeloma, showing a statistically significant PFS benefit and about 68% PFS at 18 months. OS data remain immature, with safety resembling prior profiles. Separately, FDA approved talazoparib with enzalutamide for mutated prostate cancer, offering additional near-term portfolio upside for Pfizer.

View signal analysis
PFEOct 15, 2026+0.98% since signal

Pfizer hits 52-week high as JPMorgan lifts target to $30

Pfizer rose about 3% to close at $29.21, reaching a 52-week high. JPMorgan boosted PFE's target to $30 while maintaining Neutral, signaling modest upside. The move comes amid mixed sector signals, with XAR down 1.1% and Thermo Fisher showing strength, contributing to a cautiously bullish sentiment for large-cap pharma.

View signal analysis
PFEOct 7, 2026-0.96% since signal

FDA approves TUKYSA frontline maintenance in HER2+ breast cancer, signaling growth potential for Pfizer

Pfizer announced FDA approval of TUKYSA with trastuzumab and pertuzumab for maintenance in adults with unresectable HER2+ breast cancer, expanding its use to frontline metastatic disease after induction. The move could broaden TUKYSA's addressable market and lift near-term sales if clinicians adopt the regimen and payers reimburse. The success hinges on uptake, payer coverage, and competitive dynamics in the HER2 space.

View signal analysis
PFEOct 7, 2026-1.05% since signal

Pfizer trims 330 Italian jobs at Sicily plant, signaling broader downsizing

Pfizer plans to cut about 330 jobs at its Sicily plant in Italy, per labour unions. The move underscores ongoing downsizing of Pfizer's international footprint and could affect local manufacturing capacity, though there is no stated impact on earnings guidance. Investors should monitor whether this signals broader cost-cutting or restructuring across its global operations.

View signal analysis
PFEAug 14, 2026+0.47% since signal

EMA validates PF-07307405 MAA; Pfizer-Valneva Lyme vaccine potential upside

The European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, Valneva and Pfizer’s Lyme disease vaccine candidate. While Valneva’s shares jumped on the news, Pfizer’s stock impact remains uncertain and hinges on European approval and commercialization. The milestone de-risks the program and could unlock royalties or licensing opportunities if Europe approves the vaccine.

View signal analysis
Research

Company intelligence